<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100736</url>
  </required_header>
  <id_info>
    <org_study_id>2008/W/CRC/01</org_study_id>
    <secondary_id>08/S1102/1</secondary_id>
    <nct_id>NCT01100736</nct_id>
  </id_info>
  <brief_title>Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)</brief_title>
  <official_title>Characterisation of the Role of ETA and ETB Receptors in Regulating Plasma ET-1 and the Vasodilator Response to ET-3 in Man</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Encysive Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelin-1 (ET-1) has been linked to a number of conditions including pulmonary arterial
      hypertension (PAH). ET-1 acts via 2 receptors, ETA and ETB. The ET-1 receptor blockers
      bosentan and sitaxsentan have been shown to be beneficial in patients with PAH. Bosentan
      blocks both ETA and ETB receptors. Sitaxsentan selectively blocks ETA receptors.
      Theoretically, selective ETA blockade may be associated with greater vasodilation and
      clearance of ET-1 by leaving the ETB receptor unblocked. This has not been directly studied
      in humans.

      We aim to investigate the endothelial ETB-mediated vascular responses between bosentan and
      sitaxsentan by using a ETB selective agonist (ET-3). We hypothesise that at clinically
      relevant doses:

        -  Bosentan will show evidence of ETB receptor blockade compared to sitaxsentan and
           placebo.

        -  These effects will be confirmed by 2 functional markers of ETB receptor antagonism:
           plasma ET-1 (a very sensitive, but not necessarily clinically relevant marker), and the
           forearm vasodilator response to ET-3.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma ET-1 after 7-day administration of bosentan, sitaxsentan and placebo</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Responses to ET-3 (maximum vasodilation after ET-3 administration and area under the curve of vasodilation) after bosentan compared with the results from sitaxsentan and placebo.</measure>
    <time_frame>60 mins</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Vasodilation</condition>
  <condition>Vasoconstriction</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosentan 125mg twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of bosentan therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitaxsentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitaxsentan 100mg once daily + placebo tablet will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of sitaxsentan therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of placebo therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>Bosentan 125mg tablets, orally, twice daily for 7 days</description>
    <arm_group_label>Bosentan</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitaxsentan</intervention_name>
    <description>Sitaxsentan 100mg tablets, orally, once daily for 7 days</description>
    <arm_group_label>Sitaxsentan</arm_group_label>
    <other_name>Thelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)</description>
    <arm_group_label>Sitaxsentan</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endothelin-3</intervention_name>
    <description>5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies</description>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_label>Sitaxsentan</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and post-menopausal women

          -  Age 18-70 years

          -  BMI 18-35 kg/m2

        Exclusion Criteria:

          -  Are mentally or legally incapacitated

          -  Have donated blood within the last 4 weeks

          -  Have a history of past or present drug or alcohol abuse

          -  Have participated in another clinical trial within 1 month

          -  Are considered to be at a high risk of HIV or Hepatitis B

          -  Are taking routine medicines

          -  Are women taking hormone replacement therapy

          -  Have significant medical or psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Centre, Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <name_title>Professor David Webb</name_title>
    <organization>University of Edinburgh</organization>
  </responsible_party>
  <keyword>Forearm Blood Flow</keyword>
  <keyword>Vasodilation</keyword>
  <keyword>Vasoconstriction</keyword>
  <keyword>Endothelin System</keyword>
  <keyword>Endothelin-1</keyword>
  <keyword>Endothelin-3</keyword>
  <keyword>Endothelin antagonists</keyword>
  <keyword>Bosentan</keyword>
  <keyword>Sitaxsentan</keyword>
  <keyword>Endothelin</keyword>
  <keyword>Regional Blood Flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Sitaxsentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

